Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United Sta…
$8.16-0.85%
报价 2026-11-13
市值
$419M
EV
$185.4M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -29.1%
$7.89$11.51
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PRTAProthena Corporation plc | $419M | -0.9% | – | 95.3% | – | – | – | |
| ARVNArvinas, Inc. | $446.6M | -0.7% | -4.1% | 96.8% | 47.4x | 64.2x | – | |
| CTMXCytomX Therapeutics, Inc. | $444.7M | -4.2% | -73.6% | 99.3% | – | – | – | |
| ASMBAssembly Biosciences, Inc. | $432.5M | +4.7% | +70.9% | 72.9% | 54.5x | – | – | |
| TECXTectonic Therapeutic, Inc. | $413.3M | +0.5% | – | 0% | – | – | – | |
| FENCFennec Pharmaceuticals Inc. | $410.2M | +6.6% | +59.0% | 93.7% | – | – | – | |
| BLSMBlossomHill Therapeutics, Inc. | $407.7M | -5.5% | – | 0% | – | – | – | |
| SLBTHorizon Space Acquisition II Corp. | $407.7M | -4.9% | – | 35.3% | – | – | – | |
| PBYIPuma Biotechnology, Inc. | $401.7M | -3.8% | +2.0% | 74.5% | 10.1x | 5.4x | 27.8x | |
| 同行中位数 | – | – | +2.0% | 73.7% | 47.4x | 34.8x | 27.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。